Dyne Therapeutics Inc. DYN
Super Investor & Insider
Nessuna transazione insider negli ultimi 6 mesi.
Fondi: 13F-HR alla SEC. Insider: acquisti (P) e vendite (S) in borsa da SEC EDGAR, ultimi 12 mesi.
About
Dyne Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies for genetically driven neuromuscular diseases. The company utilizes its proprietary FORCE platform to deliver targeted RNA therapies designed to overcome delivery limitations to muscle tissue and the central nervo…
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees263
TickerDYN
Statistics
Market Cap$3.15B
Revenue (TTM)—
Net Income-$446.2M
Net Margin—
EPS$-3.47
P/E-5.17
P/S—
P/B3.05
EV/EBITDA-4.51
ROE-58.9%
Dividend Yield—
Price$19.05
Data: Twelve Data · Revenue = mcap / P/S